Table 1 Baseline characteristics in 7 relapsed/refractory multiple myeloma patients.
Patient No. | Age (years) | Gender | Monoclonal Protein | Serum Monoclonal protein level (g/L) | Extramedullary disease | Previous lines | Previous ASCT | Previous CAR-T infusion | Previous CAR-T dose (×106/kg) | Bone marrow plasma cells (%) | BCMA in plasma cells (%) | HRC0202 dose (×106/kg) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 51 | Male | IgD-λ | 2.55 | No | 7 | Yes | HDS269B, HRC0202 | HRC0202: 12 | 77.40 | 89.01 | 10 |
2 | 57 | Male | IgG-κ | 1.60 | No | 4 | No | HRC0501 | 6 | 0.12 | 0.18 | 15 |
3 | 72 | Female | IgA-κ | 2.13 | No | 6 | No | HDS269B | 9 | 5.23 | 48.64 | 15 |
4 | 50 | Male | IgG-κ | 6.09 | No | 8 | No | HDS269B, HRC0501 | HRC0501: 6 | 0.67 | 0.00 | 15 |
5 | 57 | Female | IgG-λ | 2.77 | Yes | 4 | No | HRC0501 | 6 | 0.19 | 2.00 | 6 |
6 | 54 | Female | IgA-λ | 16.50 | No | 11 | No | HRC0501 | 6 | 0.64 | 17.07 | 6 |
7 | 51 | Female | IgG-κ | 4.95 | Yes | 7 | No | HRC0501 | 3 | 0.13 | 2.65 | 6 |
